CD30 is a potential therapeutic target in malignant mesothelioma

Molecular Cancer Therapeutics

Volumn 14, Issue 3, 2015, Pages 740-746

  Dabir, Snehal ^a   Kresak, Adam ^a   Yang, Michael ^a   Fu, Pingfu ^a   Wildey, Gary ^a   Dowlati, Afshin ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER INHIBITION; CELL MEMBRANE; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; MESOTHELIOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; IMMUNOCONJUGATES; LUNG NEOPLASMS; MESOTHELIOMA; SMALL CELL LUNG CARCINOMA;

EID: 84939466540     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0972     Document Type: Article

References (22)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
3. Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, et al. A recombinant immunotoxinagainst the tumor-associatedantigen mesothe-lin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther 2013;12:48-57.
4. Dunphy CH, Gardner LJ, Bee CS. Malignant mesothelioma with CD30-positivity. A case report and review of the literature. Arch Pathol Lab Med 2000;124:1077-9.
5. Durkop H, Foss HD, Eitelbach F, Anagnostopoulos I, Latza U, Pileri S, et al. Expressionofthe CD30 antigenin non-lymphoid tissues and cells.J Pathol 2000;190:613-8.
6. Kadin ME. Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol 2000;156:1479-84.
7. Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 2012;3:209-25.
8. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013;121:2715-24.
9. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10:7063-70.
10. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
11. Deng C, Pan B, O'Connor OA. Brentuximab vedotin. Clin Cancer Res 2013;19:22-7.
12. Garcia-Prats MD, Ballestin C, Sotelo T, Lopez-Encuentra A, Mayordomo JI. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. Histopathology 1998;32:462-72.
13. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vc MMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102: 1458-65.
14. Kim KM, McDonagh CF, Westendorf L, Brown LL, Sussman D, Feist T, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther 2008;7:2486-97.
15. Dabir S, Kluge A, Dowlati A. The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent. Mol Cancer Res 2009;7:1854-60.
16. Dabir S, Kluge A, Kresak A, Yang M, Fu P, Groner B, et al. Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival. Clin Cancer Res 2014;20: 5124-32.
17. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
18. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Ramaswamy S, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothe-lioma. Cancer Res 2002;62:4963-7.
19. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, et al. Global gene expression profilingofpleural mesotheliomas:overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006;66:2970-9.
20. Sharman JP, Goldschmidt JH, Burke JM, Hellerstedt BA, McIntyre K, Yasenchak CA, et al. CD30 expressioninnonlymphomatous malignancies. J Clin Oncol 30, 2012 (suppl; abstr 3069).
21. Jalal SI, Einhorn L, Shapiro GI, Hilton J, Wheler J, Dowlati A, et al. Brentuximab vedotin in patients with CD30 mesothelioma. Mesotheli-oma, thymic malignancies, and other thoracic malignancies. Int J Rad Oncol 2014;90:S8.
22. Fromm JR, McEarchern JA, Kennedy D, Thomas A, Shustov AR, Gopal AK. Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin Lymphoma Myeloma Leuk 2012;12: 280-3.